Document is current
Any future updates will be listed below
-
Authors
Moghul, Ismail
Pontikos, Nikolas
Sharma, Anitta
Liu, Timing
Soomro, Taha
Wagner, Siegfried K.
Silva, Alan Sousa
Zhang, Gongyu
Naik, Gunjan
Bagga, Pallavi
Chan, Yiu Wai
Keane, Pearse A.
Cipriani, Valentina
Sivaprasad, Sobha
Webster, Andrew R.
Balaskas, Konstantinos
-
Funding
Funding for this research was provided by:
Moorfields Eye Charity (R190001)
- License Information
-
More Information
Article History
Received: 11 November 2025
Accepted: 23 February 2026
First Online: 7 March 2026
Declaration
:
: KB has received speaker fees from Novartis, Bayer, Roche; meeting or travel fees from Novartis and Bayer; consulting fees from Novartis, Roche, Bayer and Boehringer-Ingleheim; research support from Apellis, Novartis, and Bayer; employment AAvantgarde Bio. PAK received grants or contracts by a UK Research & Innovation Future Leaders Fellowship (MR/R019050/1) and The Rubin Foundation Charitable Trust; consulting fees from Retina Consultants of America, Topcon, Roche and Boehringer-Ingleheim; payment or honoraria from Zeiss, Topcon, Novartis, Boehringer-Ingleheim, Apellis, Roche and AbbVie; support for attending meetings and/or travel from Bayer, Topcon and Roche; Active patents: Generalizable medical image analysis using segmentation and classification neural networks and Pending Patents: Predicting disease progression from tissue images and tissue segmentation maps ; participation on a Data Safety Monitoring Board or Advisory Board for Topcon, Bayer, Boehringer-Ingleheim, RetinAI and Novartis; Bitfount (stock options) and Big Picture Medical (stock). SS received grants (paid to her institution) from Bayer and Boehringer Ingelheim; consulting fees for participation on advisory boards from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Phamaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics, and Sanofi; honoraria for lectures from Bayer, and Roche, for presentations from Bayer, Roche, Astellas, and Abbvie, and for manuscript writing and educational events from Bayer, Roche, and Boehringer Ingleheim; support for attending meetings and/or travel from Boehringer Ingelheim, Roche, and Bayer; participation in Data Safety Monitoring Boards for Bayer and Novo Nordisk; is a Trustee of the Macular Society and Chair of the Royal College of Ophthalmologists’ Scientific Committee; and has stock options in Eyebiotech. All other authors declare no competing interests.
